FDA pushes for ethnic diversity in clinical trials
The EU has put on the snooze button on medical cannabis regulatory talks for the moment which came as a surprise after the expectations that seemed to be assumed with the Berlin presidency, especially since Germany is the most successful European market for medicinal hemp products at the moment. Apart from that and the 2017 drugs reform, the German government initiated the gradual domino effect in EU countries to develop policies for facilitating patient access to medical cannabis.
When the law changed, the average of 1000 prescribed patients suddenly went up 142,000 by the next year, not to mention the member states that established a Med-Cann scheme such as the Netherlands, the Czech Republic, Italy, Malta, and the U.K. It is in fact no surprise that the country has been a model and a reference for its fantastic standards in leveraging cannabis out of the war on drugs and push it towards its potential to become an asset to the medical world.
Naturally, all this became less urgent in the light of this year’s pandemic, and the creation of a European Health Data Space.
Royal College of Surgeons and the National College of Art and Design partner to develop a silicone heart model